RegeneRx completes enrollment for Phase Ia cardiac drug study
The trial includes four groups of 10 subjects each to assess the safety of escalating doses of RGN-352 injected into the blood stream. A final analysis and report
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).